Lumata Health, a leader in personalized support for patients with vision-threatening chronic eye diseases, announced that it has raised $23 million in Series B funding to accelerate its mission of eliminating preventable vision loss, bringing its total raised since inception to $36 million. This funding round was co-led by LRVHealth, McKesson Ventures, and Cencora Ventures, with participation from existing investors, including Cortado Ventures.
This funding round will enable Lumata to meet growing demand and further enhance the data-driven technology powering its patient adherence solutions.
Vision loss is a major health crisis, with the prevalence of sight-threatening conditions such as glaucoma, diabetic retinopathy, and age-related macular degeneration expected to double in the coming decades. Even though effective pharmacological treatments exist, systemic barriers continue to delay or prevent timely care for millions of patients. Lumata Health’s platform addresses these challenges by combining predictive analytics with personalized interventions—recently showing that up to 800 additional vision-saving eye injections are delivered annually for every 1,000 participating patients. This proactive model preserves sight and significantly reduces long-term healthcare costs associated with vision loss.
In the past three years, Lumata has partnered with eye care providers nationwide, including the five largest national and regional eye care networks. These collaborations have fueled rapid growth and demonstrated Lumata’s effectiveness in improving treatment adherence, enhancing patient satisfaction, and removing barriers to care. The participation of McKesson Ventures and Cencora Ventures in this round highlights the significant value Lumata brings to both practices and patients, and their expertise will further accelerate Lumata’s ability to deliver personalized care at scale.
KEY QUOTES:
“We are thrilled to partner with investors who share our vision for a smarter, more effective approach to preventing blindness from chronic eye diseases. This investment will allow us to continue scaling our data-driven approach to ensuring access and adherence to vision-saving treatments for the millions of people in the U.S. with these conditions.”
- Landon Grace, CEO of Lumata Health
“With millions of Americans at risk of preventable blindness, we’re investing in Lumata Health because it is uniquely positioned to drive meaningful change at scale. By combining advanced technology, predictive analytics, and compassionate care, the company is reshaping how chronic eye diseases are managed and ensuring that more patients retain their vision for years to come.”
- Ellen Herlacher, Partner at LRVHealth
“What impressed us most is Lumata’s potential to reduce overall healthcare costs while also generating significant value for ophthalmology practices. Their proactive, end-to-end solution not only improves patient outcomes, it creates a win-win scenario for everyone involved in the care continuum.”
- Michelle Snyder, Partner at McKesson Ventures
“As more specialty medicines reach the market, solutions designed to help patients start and stay on their prescribed treatment regimen are increasingly important. Lumata’s blend of technology and tailored support enables greater patient engagement and improved adherence to providers’ treatment plans.”
- Jason Dinger, Senior Vice President of Strategic Execution at Cencora Ventures
